Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction (NCT04210180), a na phase 2, phase 3 study. The primary outcome is Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6.

2. Clinical Question

The study description frames switching as movement from combustible cigarettes to e-cigarettes, not treatment of nicotine or tobacco dependence. It also describes a question about whether varenicline could influence the rewarding effects of combustible cigarettes or nicotine-containing e-cigarettes. Those are the rationale and context in the registry record, not demonstrated effects. The primary outcome is a participant count, and no primary outcome result is reported in the registry record. Consequently, the record does not establish how many participants met the switching definition or how precisely that count was estimated.

3. Trial Design

The record classifies this as a single-group study with no allocation and no masking. It lists phase 2 and phase 3, an enrollment of 25, and a completed status. The sponsor is Rose Research Center, LLC. The recorded study start date is 2019-11-19, and the primary completion date is 2020-10-14. These are registry entries; they do not, by themselves, describe when each participant received treatment or completed follow-up.

All enrolled participants are described under one intervention group, Varenicline plus e-cigarette. Participants received a G6 e-cigarette at V2 for ad libitum use and the varenicline starter kit at V3, along with additional G6 cartomizers. The record specifies the starter-kit schedule for days 1-7, then the description stops after the words “After the first week.” The subsequent dosing and intervention instructions are not reported in the registry record. The record does not give enough information to reconstruct the full treatment schedule.

A single-group design describes outcomes among participants who received the intervention, but it does not create a concurrent control group. Since the allocation is listed as NA, there is no randomized assignment to compare. Since masking is listed as none, the study is open-label. The registry record does not report a blinded outcome assessment. These design features matter when interpreting self-reported outcomes: the observed reports describe participants in this study, while a causal contrast against an alternative treatment or usual care is unavailable.

The study description explicitly says its intent was not to treat nicotine or tobacco dependence, but to explore switching from combustible cigarettes to e-cigarettes. The listed secondary outcome concerns point abstinence from smoking cigarettes at 6 months post-switch. The registry record lists four outcome measures, but no analysis results. Details such as the number of participants who completed each assessment, the duration of follow-up for each participant, and the statistical analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6, measured over Weeks 8-11.

The primary endpoint is a count of participants reporting continuous complete switching from cigarettes to the Halo G6 during weeks 8-11. The operational definition requires self-report of no cigarette smoking, not even a puff, since the prior session. This makes the endpoint a measure of reported cigarette abstinence across the stated assessment period. It is not a measure of stopping all nicotine use: the study’s stated aim was transition to an e-cigarette, which is also a nicotine product in the study description.

A count is a direct way to express how many participants meet a defined outcome. To interpret such a count fully, readers generally need to know the number assessed, how missing assessments were handled, and how the endpoint was summarized or analyzed. Those details, and the primary result itself, are not reported in the registry record. Enrollment of 25 is not necessarily the same as the number with an observed primary outcome, and the record does not say how many participants contributed to that endpoint.

The endpoint is used because it corresponds to the stated switching objective: cigarette abstinence while participants have access to the e-cigarette intervention. Its definition is tied to reports since a prior session, so interpretation depends on the assessment schedule and on participants’ reports. The registry record does not give further information about verification of self-report, the handling of lapses or missed visits, or whether the endpoint required reports at every relevant assessment. The listed definition should therefore be read as the stated criterion, not as evidence of a particular result or measurement procedure beyond what is described.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods are easiest to interpret when separated into the question being asked, the outcome scale, the design that generated the observations, and the analysis used to summarize them. The registry record gives some design and endpoint details, but it does not report an analysis plan or analysis results. The discussion below explains the relevant statistical concepts generally and distinguishes them from methods documented for this study.

What does a count endpoint represent?

The primary outcome is a count of participants meeting a binary definition: each participant either meets the stated switching criterion or does not. A count can be informative, but it is most interpretable alongside the number of participants assessed and a clear rule for participants whose outcome is unknown. The enrollment figure is 25; the record does not state that all 25 had an observed primary outcome. The number assessed for the primary endpoint and the treatment of missing outcome data are not reported in the registry record.

For a binary outcome, an estimate may be expressed as a count or as a proportion, with an interval describing uncertainty. A confidence interval is a range of values compatible with the observed data under a specified statistical model and procedure. It conveys precision rather than the probability that a particular treatment effect is true. No confidence interval for the primary endpoint is reported in the registry record, and no value can be inferred from the endpoint definition alone.

What does the single-group design permit?

A single-group study observes outcomes in participants exposed to the study intervention, without a concurrent comparison group. Descriptive summaries can report what was observed in that group. A comparative treatment effect, however, requires a contrast between outcomes under different conditions. Random allocation is one way to support that contrast by making treatment assignment independent of participant characteristics on average. Here, allocation is listed as NA and the model as single-group, so no randomized contrast is available.

In a one-group study, a change over time or an observed outcome cannot on its own identify the effect of the intervention. Other influences may coincide with treatment, including participant selection, changes in behavior, the passage of time, or measurement conditions. This is a general limitation of the design, not a claim that any particular influence affected this study. The registry record does not report a comparator or an adjusted analysis intended to address such influences.

Why does outcome definition matter?

The primary definition specifies self-report of no cigarette smoking, not even a puff, since the prior session, during the weeks 8-11 timeframe. A tightly defined endpoint helps make the outcome interpretable, but readers also need to understand how assessments were scheduled and how reports were combined into the final classification. The record does not explain whether every assessment had to meet the criterion, how lapses were handled, or how missed sessions affected classification. Those details are not reported in the registry record.

Self-reported outcomes can be affected by recall and reporting behavior. In an open-label study, participants know the intervention they receive; that knowledge can be relevant when considering subjective or reported outcomes. This general consideration does not establish that reports were inaccurate. The record does not describe independent adjudication or verification, so no further measurement procedure should be assumed.

How should uncertainty and statistical significance be read?

Statistical uncertainty reflects the fact that an estimate from a group of participants may vary across samples. A confidence interval can show the range of estimates reasonably consistent with the data under its assumptions. A p-value, when reported, measures how incompatible the data are with a specified null model; it does not measure the clinical importance of an outcome or the probability that a treatment works. Neither a p-value nor an interval for the primary endpoint appears in the registry record. Statistical significance therefore cannot be assessed from the posted information.

A single-group count could be summarized descriptively, but any inferential analysis would depend on the statistical model and assumptions. For example, intervals for a binary outcome rely on assumptions about how participant outcomes are represented and how uncertainty is calculated. The registry record does not report which procedure, if any, was used for the primary outcome. No method should be attributed to the study without that documentation.

What is the role of planning calculations?

A sample-size planning illustration is not an observed trial result and is not a measure of the probability that the study will find a statistically significant result. The planning description associated with this record uses a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a stated fraction of an observed effect. For time-to-event outcomes, the description refers to total events; for other outcomes, it refers to participants per arm. These are generic illustration assumptions, not evidence that the single-group study had a two-arm design or used those assumptions in its protocol.

The registry record does not report the trial’s own sample-size justification. It also does not report a statistical analysis plan, interim analyses, or a prespecified method for handling the primary outcome. The presence of a planning illustration cannot fill those gaps. Planning calculations depend on assumptions about the effect to be detected, outcome variability, allocation, and analysis; when assumptions differ from the actual design, the illustration may not describe the study’s planned or achieved precision.

Why does over-dispersion matter in general?

Over-dispersion occurs when observed variability is greater than expected under a statistical model. If a model assumes less variability than the data actually contain, standard errors can be too small and confidence intervals too narrow, creating an overly confident impression. Methods that account for extra variability can produce more appropriate uncertainty estimates. This is a general concept and is not a reported feature of this study: the primary endpoint is a participant count, and the registry record does not report an over-dispersion assessment or a model for the endpoint.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Varenicline Plus E-cigarette")
n      <- c(25)
events <- c(8)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Varenicline Plus E-cigarette  25  8  32.0  14.9  53.5  17.2  51.6  17.2  51.8

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists four outcome measures, including the primary switching outcome and a secondary outcome for point abstinence from smoking cigarettes at 6 months post-switch. It does not report a multiplicity strategy, a hierarchy for testing outcomes, or which outcomes were intended for confirmatory statistical testing. Multiplicity is a general concern when several hypotheses are tested: the more tests conducted, the greater the chance of obtaining at least one apparently unusual result by chance if each test is interpreted independently. Adjustment or a prespecified testing hierarchy can address that concern, but no such procedure is reported.

The record lists zero analyses and does not post outcome estimates for the primary or secondary endpoints. It therefore does not provide a basis for reviewing statistical tests, covariate adjustments, model choices, or whether analyses followed a prespecified plan. A missing analysis listing does not establish that no analysis was performed; it means the analysis details are not reported in the registry record.

Missing-data handling is not reported in the registry record. For a self-reported switching endpoint, the way unobserved visits or incomplete follow-up are classified can affect the resulting count. Common approaches in general include excluding participants without an endpoint assessment, treating missing outcomes as failures, or using a model that accommodates incomplete observations. Each approach carries assumptions and can lead to different interpretations. None should be attributed to this study without documentation.

The analysis population is also not reported in the registry record. The record does not say whether the primary result was intended to include everyone enrolled, only participants who received the intervention, or another defined set. Enrollment of 25 should not be mistaken for an endpoint analysis denominator. No inferential conclusion can be drawn without knowing which participants were analyzed and how their missing assessments were treated.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: allergic reaction to lidocaine (4.0%).

For the Varenicline Plus E-cigarette group, the registry record reports one participant with a serious adverse event among 25 at risk, 22 participants with other adverse events among 25 at risk, and zero deaths among 25 at risk. These are participant counts as listed in the record. They should be read separately: the serious-event figure concerns the serious category, while the other-event figure concerns the other category. The registry record does not provide enough detail to determine the nature, timing, duration, or overlap of individual events.

The listed top serious term is allergic reaction to lidocaine, at 4.0%. The record does not explain the circumstances, timing, or relationship of that event to study treatment. A reported adverse event is not, by itself, evidence that the intervention caused it. The study has no comparison group, so the posted safety figures cannot quantify how event frequency differed from an alternative condition.

The record does not report exposure time, a detailed event listing, severity grades for other events, or the rules used to attribute events. The figures are therefore a limited description of recorded events, not a complete comparative assessment of safety. The zero-death count means that no deaths are listed for the group in this record; it does not answer other safety questions.

13. What the Result Does, and Does Not, Mean

The study record describes a completed, open-label, single-group investigation of varenicline together with a G6 e-cigarette, with the stated aim of exploring transition from combustible cigarettes to e-cigarettes. Its primary endpoint is self-reported continuous complete switching during weeks 8-11. These details establish the question the study was designed to address, but the registry record does not report the primary endpoint result.

Without the observed count and the number assessed, it is not possible to describe how often participants met the switching definition. Without an uncertainty estimate, the precision of any such result cannot be judged. The enrollment of 25 is the registered enrollment, not a reported primary endpoint denominator. The record also does not report the secondary outcome result for point abstinence at 6 months post-switch.

The single-group design does not support a direct comparison with another treatment or with no intervention. Consequently, even a reported count would describe outcomes in this group rather than establish that varenicline, the e-cigarette, or their combination caused switching. The absence of allocation to a comparator is especially important because the study rationale raises competing possibilities about varenicline’s effect on the rewarding properties of cigarettes and e-cigarettes. The record supplies no outcome result with which to assess those possibilities.

The endpoint concerns cigarette smoking, not abstinence from all nicotine or tobacco products. The study description explicitly frames the aim as a switch to a different tobacco product rather than treatment of dependence. Thus, the primary outcome should not be interpreted as cessation of all nicotine use. The record does not report a measure of complete nicotine abstinence as the primary endpoint.

The safety counts describe adverse events recorded in the intervention group, including one serious adverse event and no deaths. Without a comparator and additional event details, those figures do not establish a causal relationship or provide a comparative risk estimate. Overall, the registry record identifies a clinically relevant switching question and a limited set of design and safety details, but does not provide the efficacy outcomes or analysis information needed to quantify the observed switching result.

14. Why This Trial Matters Statistically

This study is statistically notable for the distinction between a clinically understandable aim and the kind of inference its design can support. Switching from combustible cigarettes to an e-cigarette is a defined behavioral outcome, and the record specifies a particular period and a self-report criterion. That clarity helps readers identify what would count as the primary outcome. At the same time, the single-group design means the outcome cannot be contrasted with a concurrent control condition.

The study rationale also presents an inherently two-sided question: varenicline might reduce the rewarding effects of combustible cigarettes and facilitate switching, or it might reduce the rewarding effects of nicotine-containing e-cigarettes and impede transition. A comparative design and reported outcome estimates could help distinguish patterns across conditions. The registry record instead lists a single group and does not report the primary result, so neither possibility can be assessed from the posted information.

The record illustrates why endpoint definitions, denominators, and missing-data rules matter. A participant count is meaningful only alongside the number assessed and the classification of incomplete follow-up. Those details are not reported in the registry record. Likewise, an analysis plan and uncertainty estimates are necessary for assessing precision and inferential strength, but they are not reported.

The distinction between switching and cessation is also important for statistical interpretation. The primary endpoint concerns cigarette abstinence while the study’s stated objective is transition to e-cigarettes. It therefore addresses a narrower question than whether participants stopped using nicotine or tobacco products. Accurate interpretation depends on keeping the endpoint aligned with the study’s stated aim rather than treating all forms of abstinence as interchangeable.

These features make the study useful to discuss as a design and measurement example, while the available registry information remains insufficient to quantify an outcome effect or support comparative conclusions.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed for a full interpretation are not reported in the registry record. The primary switching result is absent, as are its analysis denominator, uncertainty estimate, and any statistical test. The record lists enrollment of 25 but does not establish how many participants were assessed at weeks 8-11 or how the primary outcome was summarized.

The intervention description is incomplete. It gives the initial varenicline schedule and states that participants received a G6 e-cigarette and additional cartomizers, but the regimen description ends after “After the first week.” The remaining dosing instructions, duration of treatment, adherence information, and details of intervention delivery are not reported in the registry record.

The record does not report eligibility criteria, baseline participant characteristics, the visit schedule, or the procedures used to collect and verify self-reported cigarette abstinence. It also does not explain how incomplete follow-up or missing assessments were handled. Those omissions limit assessment of the endpoint and of how representative the observed participants may have been.

The design is single-group, with no allocation and no masking. There is no concurrent control for interpreting either switching outcomes or adverse events. The registry record does not report an analysis plan, sample-size justification, interim analyses, multiplicity procedures, or a defined analysis population. These details cannot be inferred from the listed phase, enrollment, or completion status.

Finally, the adverse-event summary is limited to participant counts and a listed serious term. The record does not report event timing, detailed descriptions, attribution, or exposure duration. These limitations restrict interpretation of the safety figures and prevent comparative safety conclusions.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction — NCT04210180.
• Registry record last updated 2022-02-24; status last verified 2022-02.
• Results first posted 2022-02-08.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes NCT04210180, Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction, sponsored by Rose Research Center, LLC. It lists phase 2 and phase 3, enrollment of 25, a completed status, and a single-group, open-label design with allocation listed as NA. The recorded start date is 2019-11-19, and the primary completion date is 2020-10-14.

The intervention group combined varenicline with a G6 e-cigarette. The primary endpoint was the number of participants reporting continuous complete switching from cigarettes during weeks 8-11, defined by self-report of no cigarette smoking, not even a puff, since the prior session. A secondary outcome concerns point abstinence from smoking cigarettes at 6 months post-switch.

The registry record does not report primary or secondary outcome results, analysis methods, missing-data handling, or the analysis population. Safety figures list one participant with a serious adverse event, 22 with other adverse events, and zero deaths; allergic reaction to lidocaine is listed at 4.0% as a top serious term.